References
- Mocellin S, Nitti D. Gastrointestinal carcinoid: epidemiological and survival evidence from a large population-based study (n = 25 531). Ann Oncol 2013;24:3040-4
- Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 38,825 cases in the United States. J Clin Oncol 2008;26:3063-72
- Lawrence B, Kidd M, Svejda B, et al. A clinical perspective on gastric neuroendocrine neoplasia. Curr Gastroenterol Rep 2011;13:101-9
- Horton KM, Kamel I, Hofmann L, et al. Carcinoid tumors of the small bowel: a multitechnique imaging approach. Am J Roentgenol 2004;182:559-67
- Halperin DM, Shen C, Dasari A, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol 2017;18:525-34
- Food and Drug Administration. Orphan drugs, 21 C.F.R. Sect. 316.300(1)(d). Silver Spring, MD, USA: U.S. Food and Drug Administration; 2017
- Crocetti E, Paci E. Malignant carcinoids in the USA, SEER 1992–1999. An epidemiological study with 6830 cases. Eur J Cancer Prev 2003;12:191-4
- National Cancer Institute. Gastrointestinal carcinoid tumors treatment. Bethesda, MD, USA: NCI. Available at: https://www.cancer.gov/types/gi-carcinoid-tumors/hp/gi-carcinoid-treatment-pdq#link/_219_toc
- Broder MS, Chang E, Romanus D, et al. Healthcare and economic impact of diarrhea in patients with carcinoid syndrome. World J Gastroenterol 2016;22:2118-25
- National Comprehensive Cancer Network. NCCN guidelines, version 2.02. Neuroendocrine tumours. Fort Washington, PA, USA: NCCN. 2014. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
- Novartis Pharmaceuticals Corporation. Sandostatin® (octreotide acetate) Prescribing Information. East Hanover, NJ, USA: Novartis Pharmaceuticals; 2012. Available at: https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/sandostatin_inj.pdf
- Novartis Pharmaceuticals Corporation. Sandostatin LAR® (octreotide acetate) Prescribing Information. East Hanover, NJ, USA: Novartis Pharmaceuticals; 2012. Available at: https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/sandostatin_lar.pdf
- Gut P, Waligórska-Stachura J, Czarnywojtek A, et al. Management of the hormonal syndrome of neuroendocrine tumors. Arch Med Sci 2017;13:515-24
- Boudreaux JP, Klimstra DS, Hassan MM, et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors. Pancreas 2010;39:753-66
- Liu Q, Yang Q, Sun W, et al. Discovery and characterization of novel tryptophan hydroxylase inhibitors that selectively inhibit serotonin synthesis in the gastrointestinal tract. J Pharmacol Exp Ther 2008;325:47-55
- Lapuerta P, Zambrowicz B, Fleming D, et al. Telotristat etiprate, a novel inhibitor of serotonin synthesis for the treatment of carcinoid syndrome. Clin Invest 2015;5:447-56
- Lexicon Pharmaceuticals, Inc. Xermelo® (telotristat ethyl) Prescribing Information. Basking Ridge, NJ, USA: Lexicon Pharmaceuticals, Inc; 2017. Available at: https://www.xermelo.com/Media/Default/pdfs/Product_Info_telotristat_etiprate.pdf
- Kulke MH, Hörsch D, Caplin ME, et al. Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome. J Clin Oncol 2017;35:14-23
- Schafer J, Galante D, Shafrin J. Value tools in managed care decision making: current hurdles and future opportunities. J Manag Care Pharm 2017;23:S21-S7
- Ollendorf DA, Chapman R, Pearson SD. Assessing the effectiveness and value of drugs for rare conditions. Institute for Clinical and Economic Review Technical Brief for the ICER Orphan Drug Assessment and Pricing Summit. Boston, MA, USA: Institute for Clinical and Economic Review; May 2017. Available at: https://icer-review.org/wp-content/uploads/2017/02/ICER_Assessing-the-Value-of-Drugs-for-Rare-Conditions_051017.pdf
- National Institute for Health and Care Excellence. NICE and NHS England consultation on changes to the arrangements for evaluating and funding drugs and other health technologies assessed through NICE’s technology appraisal and highly specialised technologies programmes. London, United Kingdom: National Institute for Health and Care Excellence; 2017. Available at: https://www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-technology-appraisals/board-paper-TA-HST-consultation-mar-17-HST-only.pdf
- Institute for Clinical and Economic Review. Proposed adaptation of the ICER value framework for the assessment of treatments for ultra-rare conditions. Boston, MA, USA: Institute for Clinical and Economic Review; July 2017. Available at: https://icer-review.org/wp-content/uploads/2017/05/ICER_Proposed_VAF_Adaptations_Orphan_Drugs_072517.pdf
- Tsai HH, Punekar YS, Morris J, et al. A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther 2008;28:1230-9
- Toumpanakis C, Garland J, Marelli L, et al. Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR. Aliment Pharmacol Ther 2009;30:733-40
- Öberg K, Knigge U, Kwekkeboom D, et al. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(suppl 7):124-30
- Strosberg J, Weber J, Feldman M, et al. Above-label doses of octreotide-LAR in patients with metastatic small intestinal carcinoid tumors. Gastrointest Cancer Res 2013;6:81-5
- van der Horst-Schrivers AN, Post WJ, Kema IP, et al. Persistent low urinary excretion of 5-HIAA is a marker for favourable survival during follow-up in patients with disseminated midgut carcinoid tumours. Eur J Cancer 2007;43:2651-7
- Burton T, Lapuerta P. Carcinoid syndrome: economic analysis of dose escalation with somatostatin analogues. J Manag Care Pharm 2016;22:S24
- Beaumont JL, Cella D, Phan AT, et al. Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas 2012;41:461-6
- Arseneau KO, Sultan S, Dawn T, et al. Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis? Clin Gastroenterol Hepatol 2006;4:1135-42
- Food and Drug Administration. Ulcerative colitis: clinical trial endpoints guidance for industry. Silver Spring, MD, USA: U.S. Food and Drug Administration. Available at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm
- Rao SSC, Holdsworth CD, Read NW. Symptoms and stool patterns in patients with ulcerative colitis. Gut 1988;29:342-5
- Orchard TR, van der Geest SAP, Travis SPL. Randomised clinical trial: early assessment after 2 weeks of high-dose mesalazine for moderately active ulcerative colitis: new light on a familiar question. Aliment Pharmacol Ther 2011;33:1028-35
- Collins P, Rhodes J. Ulcerative colitis: diagnosis and management. Br Med J 2006;333:340-3
- Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. Oxford: Oxford University Press; 1996
- Institute for Clinical and Economic Review. Overview of the ICER value assessment framework and update for 2017–2019. Boston, MA, USA. Available at: https://icer-review.org/wp-content/uploads/2017/06/ICER-value-assessment-framework-update-FINAL-062217.pdf
- Pavel M, Hörsch D, Anthony L, et al. Patients interviewed in TELESTAR, a phase 3 study of telotristat etiprate, report meaningful improvement in carcinoid syndrome. Presented at the Annual Meeting of the European Neuroendocrine Tumor Society (ENETS); March 9–11, 2016; Barcelona, Spain
- Hudgens S, Gable J, Kulke M, et al. Evaluation of meaningful change in bowel move frequency for patients with carcinoid syndrome. J Clin Oncol 2017;35(suppl 4):583